daily use for PCOS
A systematic review and meta-analysis of RCTs found that daily dosing was more effective than every-three-day dosing for hirsutism and produced lower androstenedione levels in women with PCOS.
Hypothesized mechanism
More frequent (daily) anti-androgen dosing achieves greater androgen suppression, lowering androstenedione and improving hirsutism.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 6 of 10 overall, a moderate reading, from a direct rated moderate in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Evidence comes from a single systematic review and meta-analysis of RCTs (the anti-androgen review), which counts as one synthesis rather than independent replication. Per scoring rules, a single meta-analysis scores 1 and does not reach the threshold for 2.
Rigor
The source is a systematic review and meta-analysis of randomised controlled trials, which is high on the design hierarchy. Claim 2 reports a pooled effect with a confidence interval and I2 = 0%, consistent with quantitative meta-analysis.
Specificity
The condition PCOS is named directly in the source title, and hirsutism/androstenedione outcomes are described. However, 'daily use' as the intervention is non-specific — the actual drug/anti-androgen is not identified in the claims, weakening specificity.
Plausibility
The claims show that more frequent (daily) dosing lowers androstenedione and improves hirsutism, implying a dose-frequency mechanism via androgen reduction. This is plausible and supported by the androstenedione data, but the underlying mechanism is not explicitly evidenced beyond the association.
Consistency
Both claims point in the same direction (daily use superior to every-three-days dosing for hirsutism and androstenedione). They derive from a single meta-analysis source, so independent cross-source consistency cannot be established, warranting a neutral score.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Daily use was more effective for hirsutism than use every three days PubMed · PMID 37583655 ↗
- 2resulted in lower androstenedione levels (-0.30 ng/ml [-0.50, -0.10], p = 0.004; I2 = 0%) PubMed · PMID 37583655 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →